Expanded Access Policy

Arcellx is committed to reimagining cell therapy through the development of innovative immunotherapies for patients with cancer and other incurable diseases.

Because of the complexity of engineering our cell therapies and our current phase of clinical development, we currently provide access to our investigational therapies (i.e., those that have not yet been approved by regulatory authorities such as the Food and Drug Administration in the United States) only through clinical trials.

We design, conduct and monitor our clinical trials to evaluate the efficacy, safety and tolerability of our investigational therapies with the highest scientific rigor. We plan to submit the results from our clinical trials to regulatory agencies for review with the goal of making our therapies broadly available to patients. We recommend that patients interested in our investigational therapies discuss with their physician whether they may be a fit for any of our clinical trials.

Information about our clinical trials is available on the Clinical Trials section of our website or on the National Institutes of Health’s (NIH) website http://www.clinicaltrials.gov by searching for “Arcellx.”

If you are a health care professional and have questions about participating in one of our clinical studies or about one of our investigational therapies, please email  [email protected] and our team will respond as soon as possible.

In accordance with the 21st Century Cures Act, we may revise this policy at any time.